Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. company information, Employees & Contact Information

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

Company Details

Employees
197
Founded
-
Address
10865 Road To The Cure,
Phone
(310) 358-3200
Email
in****@****cor.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, CA - California
Looking for a particular Capricor Therapeutics, Inc. employee's phone or email?

Capricor Therapeutics, Inc. Questions

News

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel - GlobeNewswire

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel GlobeNewswire

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine - Yahoo Finance

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine Yahoo Finance

Capricor Therapeutics Provides Regulatory Update on - GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on GlobeNewswire

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA - GlobeNewswire

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy - GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy - GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy GlobeNewswire

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program - GlobeNewswire

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program GlobeNewswire

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewswire

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire

Capricor Therapeutics Announces Positive 4-Year Data from - GlobeNewswire

Capricor Therapeutics Announces Positive 4-Year Data from GlobeNewswire

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer - GlobeNewswire

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer GlobeNewswire

Capricor Therapeutics Announces Orphan Drug Designation for - GlobeNewswire

Capricor Therapeutics Announces Orphan Drug Designation for GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 (NASDAQ:CAPR) - Seeking Alpha

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 (NASDAQ:CAPR) Seeking Alpha

Capricor Therapeutics Schedules FDA Meeting to Discuss Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative

Capricor Therapeutics Schedules FDA Meeting to Discuss Deramiocel BLA for Duchenne Muscular Dystrophy Quiver Quantitative

Capricor Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative

Capricor Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 Quiver Quantitative

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency - Yahoo Finance

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency Yahoo Finance

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock - GlobeNewswire

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock GlobeNewswire

Critical Duchenne Treatment Milestone: Capricor Reveals Latest Deramiocel BLA Progress in Tomorrow's Webinar - Stock Titan

Critical Duchenne Treatment Milestone: Capricor Reveals Latest Deramiocel BLA Progress in Tomorrow's Webinar Stock Titan

Capricor Therapeutics Signs Binding Term Sheet with Nippon - GlobeNewswire

Capricor Therapeutics Signs Binding Term Sheet with Nippon GlobeNewswire

Capricor Therapeutics Announces Collaboration with the - GlobeNewswire

Capricor Therapeutics Announces Collaboration with the GlobeNewswire

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors - GlobeNewswire

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors GlobeNewswire

Capricor Therapeutics and Nippon Shinyaku Enter Partnership - GlobeNewswire

Capricor Therapeutics and Nippon Shinyaku Enter Partnership GlobeNewswire

Capricor Announces 12-Month Results from HOPE-1 Trial in Duchenne Muscular Dystrophy to be Presented at AHA Late-Breaking Session - PR Newswire

Capricor Announces 12-Month Results from HOPE-1 Trial in Duchenne Muscular Dystrophy to be Presented at AHA Late-Breaking Session PR Newswire

Capricor Therapeutics to Present at 2017 BIO International Convention - PR Newswire

Capricor Therapeutics to Present at 2017 BIO International Convention PR Newswire

Top Capricor Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant